225 related articles for article (PubMed ID: 27554136)
1. Smyd3-associated regulatory pathways in cancer.
Giakountis A; Moulos P; Sarris ME; Hatzis P; Talianidis I
Semin Cancer Biol; 2017 Feb; 42():70-80. PubMed ID: 27554136
[TBL] [Abstract][Full Text] [Related]
2. Smyd3 Is a Transcriptional Potentiator of Multiple Cancer-Promoting Genes and Required for Liver and Colon Cancer Development.
Sarris ME; Moulos P; Haroniti A; Giakountis A; Talianidis I
Cancer Cell; 2016 Mar; 29(3):354-366. PubMed ID: 26908355
[TBL] [Abstract][Full Text] [Related]
3. Therapeutical potential of deregulated lysine methyltransferase SMYD3 as a safe target for novel anticancer agents.
Rajajeyabalachandran G; Kumar S; Murugesan T; Ekambaram S; Padmavathy R; Jegatheesan SK; Mullangi R; Rajagopal S
Expert Opin Ther Targets; 2017 Feb; 21(2):145-157. PubMed ID: 28019723
[TBL] [Abstract][Full Text] [Related]
4. SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells.
Hamamoto R; Furukawa Y; Morita M; Iimura Y; Silva FP; Li M; Yagyu R; Nakamura Y
Nat Cell Biol; 2004 Aug; 6(8):731-40. PubMed ID: 15235609
[TBL] [Abstract][Full Text] [Related]
5. Lysine methylation in cancer: SMYD3-MAP3K2 teaches us new lessons in the Ras-ERK pathway.
Colón-Bolea P; Crespo P
Bioessays; 2014 Dec; 36(12):1162-9. PubMed ID: 25382779
[TBL] [Abstract][Full Text] [Related]
6. SMYD3 links lysine methylation of MAP3K2 to Ras-driven cancer.
Mazur PK; Reynoird N; Khatri P; Jansen PW; Wilkinson AW; Liu S; Barbash O; Van Aller GS; Huddleston M; Dhanak D; Tummino PJ; Kruger RG; Garcia BA; Butte AJ; Vermeulen M; Sage J; Gozani O
Nature; 2014 Jun; 510(7504):283-7. PubMed ID: 24847881
[TBL] [Abstract][Full Text] [Related]
7. The SMYD3-MAP3K2 signaling axis promotes tumor aggressiveness and metastasis in prostate cancer.
Ikram S; Rege A; Negesse MY; Casanova AG; Reynoird N; Green EM
Sci Adv; 2023 Nov; 9(46):eadi5921. PubMed ID: 37976356
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of SMYD3 Is Predictive of Unfavorable Prognosis in Hepatocellular Carcinoma.
Fei X; Ma Y; Liu X; Meng Z
Tohoku J Exp Med; 2017 Nov; 243(3):219-226. PubMed ID: 29187705
[TBL] [Abstract][Full Text] [Related]
9. Amplification of SMYD3 promotes tumorigenicity and intrahepatic metastasis of hepatocellular carcinoma via upregulation of CDK2 and MMP2.
Wang Y; Xie BH; Lin WH; Huang YH; Ni JY; Hu J; Cui W; Zhou J; Shen L; Xu LF; Lian F; Li HP
Oncogene; 2019 Jun; 38(25):4948-4961. PubMed ID: 30842588
[TBL] [Abstract][Full Text] [Related]
10. Histone lysine methyltransferase SMYD3 promotes oral squamous cell carcinoma tumorigenesis via H3K4me3-mediated HMGA2 transcription.
Yang Z; Liu F; Li Z; Liu N; Yao X; Zhou Y; Zhang L; Jiang P; Liu H; Kong L; Lang C; Xu X; Jia J; Nakajima T; Gu W; Zheng L; Zhang Z
Clin Epigenetics; 2023 May; 15(1):92. PubMed ID: 37237385
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of SMYD3 and matrix metalloproteinase-9 are associated with poor prognosis of patients with gastric cancer.
Liu Y; Liu H; Luo X; Deng J; Pan Y; Liang H
Tumour Biol; 2015 Jun; 36(6):4377-86. PubMed ID: 25627005
[TBL] [Abstract][Full Text] [Related]
12. SMYD3: a regulator of epigenetic and signaling pathways in cancer.
Bernard BJ; Nigam N; Burkitt K; Saloura V
Clin Epigenetics; 2021 Feb; 13(1):45. PubMed ID: 33637115
[TBL] [Abstract][Full Text] [Related]
13. SMYD3 promotes hepatocellular carcinoma progression by methylating S1PR1 promoters.
Zhang H; Zheng Z; Zhang R; Yan Y; Peng Y; Ye H; Lin L; Xu J; Li W; Huang P
Cell Death Dis; 2021 Jul; 12(8):731. PubMed ID: 34301921
[TBL] [Abstract][Full Text] [Related]
14. Cooperation between SMYD3 and PC4 drives a distinct transcriptional program in cancer cells.
Kim JM; Kim K; Schmidt T; Punj V; Tucker H; Rice JC; Ulmer TS; An W
Nucleic Acids Res; 2015 Oct; 43(18):8868-83. PubMed ID: 26350217
[TBL] [Abstract][Full Text] [Related]
15. SMYD3 overexpression was a risk factor in the biological behavior and prognosis of gastric carcinoma.
Liu Y; Luo X; Deng J; Pan Y; Zhang L; Liang H
Tumour Biol; 2015 Apr; 36(4):2685-94. PubMed ID: 25472580
[TBL] [Abstract][Full Text] [Related]
16. Novobiocin decreases SMYD3 expression and inhibits the migration of MDA-MB-231 human breast cancer cells.
Luo XG; Zou JN; Wang SZ; Zhang TC; Xi T
IUBMB Life; 2010 Mar; 62(3):194-9. PubMed ID: 20039369
[TBL] [Abstract][Full Text] [Related]
17. SMYD3 promotes cancer invasion by epigenetic upregulation of the metalloproteinase MMP-9.
Cock-Rada AM; Medjkane S; Janski N; Yousfi N; Perichon M; Chaussepied M; Chluba J; Langsley G; Weitzman JB
Cancer Res; 2012 Feb; 72(3):810-20. PubMed ID: 22194464
[TBL] [Abstract][Full Text] [Related]
18. [Inhibition of SMYD3 gene expression by RNA interference induces apoptosis in human hepatocellular carcinoma cell line HepG2].
Xu JY; Chen LB; Xu JY; Yang Z; Wei HY; Xu RH
Ai Zheng; 2006 May; 25(5):526-32. PubMed ID: 16687068
[TBL] [Abstract][Full Text] [Related]
19. Upregulated SMYD3 promotes bladder cancer progression by targeting BCLAF1 and activating autophagy.
Shen B; Tan M; Mu X; Qin Y; Zhang F; Liu Y; Fan Y
Tumour Biol; 2016 Jun; 37(6):7371-81. PubMed ID: 26676636
[TBL] [Abstract][Full Text] [Related]
20. SMYD3 regulates the abnormal proliferation of non-small-cell lung cancer cells via the H3K4me3/ANO1 axis.
Zhong D; Zhan Z; Zhang J; Liu Y; He Z
J Biosci; 2022; 47():. PubMed ID: 36222132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
